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Volume 57, Number 5S Abstracts 21Sabdominal aortic aneurysm (CAAA) is unknown. This
study compares 30-day outcomes of these procedures
from two high volume centers, where FEVAR was under-
taken for “high risk” patients.
Methods: Patients undergoing commercially available
FEVAR and OR of CAAA (total suprarenal/visceral clamp
position) were propensity matched to identify demo-
graphic/clinical and anatomically similar cohorts. Peri-
operative outcomes were evaluated using univariate and
multivariate methods.
Results: From 7/01-8/12 59 FEVAR and 324 OR
patients were identiﬁed. Following (1:4) propensity match-
ing for age, gender, hypertension, CHF, CAD, COPD,
CVA, diabetes, preoperative creatinine and anticipated/
actual aortic clamp site, the study cohort consisted of 42
FEVAR and 147 open repairs. The most frequent FEVAR
construct was 2 renal fenestrations +/ single mesenteric
scallop in 50% of cases. Univariate analysis demonstrated
FEVAR had a higher 30 day mortality (8.7% vs 2%; P ¼
.05), any complication (41% vs 23%; P ¼ .01), procedural
complication (24% vs 7%; P < .01), and graft complication
(30% vs 2%; P < .01). Multivariate analysis identiﬁed
FEVAR had an increased 30 day mortality (OR, 5.1; 95%
CI, 1.1-24; P ¼ .04), risk of any complication (OR, 2.3;
95% CI, 1.1-4.9; P ¼ .01), and graft complication (OR,
24; 95% CI, 4.8-66; P < .01).
Conclusions: FEVAR, in this two center study, is
associated with a signiﬁcantly higher risk of peri-operative
mortality and morbidity than OR in CAAA. These data
suggest that extension of the paradigm comparing EVAR
to OR for routine AAA, to patients with CAAA is not
appropriate. Studies should ﬁrst establish proper patient
selection for FEVAR over OR before widespread use
should be considered.
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Video Presentation
Two-VesselFenestrationofGoreC3ExcluderEndograft
for Treatment of AAA in a High-Risk Patient With
Unfavorable Anatomy for Conventional EVAR
Amy Coulter, Tze-Woei Tan, Wayne W. Zhang. LSU
Health Sciences Center Shreveport, Shreveport, LA
Background: High risk patientswithAAA and anatomy
not suited for conventional endovascular repair have limited
options for treatment. The Gore Excluder endograft can
be reconstrained after deployment with the development
of the C3 delivery system and now can be utilized for
physician-modiﬁed fenestrated endovascular repair.
Technical Description: 1. Preoperative planning for
fenestration of a Gore C3 Excluder aortic endograft
using 3D reconstruction of a CT angiogram. A clock-
face orientation is used. 2. A 20F sheath is loaded ontothe delivery catheter for the aortic endograft. 3. The
endograft is partially deployed in a sterile fashion on
a back table. 4. The location of the fenestrations are
measured and marked. Fenestrations should be cut to
precisely the size of the renal artery oriﬁces or slightly
smaller. 5. The fenestrations are made. This was initially
attempted with an aortic punch, however it was much
simpler to simply cut the PTFE sharply. Wire-cutters
may be needed to cut any stent struts which impinge
on the fenestrations. 6. Radio-opaque snare wires are
sutured around the fenestrations and additional markers
are sutured to the endograft for orientation. 7. The
fenestrations are precannulated with 0.014 wires. 8.
The endograft is reconstrained using silk ties and umbil-
ical tape and loaded into the 20F sheath on the delivery
catheter. A Freer elevator is helpful in loading the supe-
rior portion of the main body which has metal anchors
which project out from the endograft. 9. The renal
arteries and SMA are identiﬁed with angiography. 10.
The main body is advanced to the level of the SMA
and the renal arteries are cannulated through the fenes-
trations with the 0.014 wires. The wires are then
exchanged for stiff wires and 6F guiding sheaths are
placed in the renal arteries. 11. The main body is
deployed. 12. Covered stent-grafts are deployed in the
renal arteries and ﬂared into the aortic endograft. 13.
The remainder of the procedure is ﬁnished in a conven-
tional fashion.
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Aortic Remodeling After Endovascular Treatment of
Complicated Type B Aortic Dissection Using
a Composite Device Design: A Report from the
STABLE Trial
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Objectives: We report aortic remodeling from the
STABLE trial, a prospective, multicenter study evaluating
safety and effectiveness of a pathology-speciﬁc endovascular
system (proximal stent-graft and distal bare metal stent) for
the treatment of complicated type B aortic dissection
(cTBAD).
Methods: All 86 enrolled patients (mean age 59 years;
73% male) were treated within 90 days of symptom onset
(64% treated within 14 days). Aortic remodeling through
2 years was assessed in patients with available aortic size
data (as of April 2012).
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patient survival was 88% at 1 year and 85% at 2 years.
From baseline to 2 years (Fig), the true lumen diameter
increased signiﬁcantly in the descending thoracic aorta
(DTA) and the more distal abdominal aorta (AA), with
a concomitant decrease in false lumen diameter. Trans-
aortic growth (>5 mm) occurring at any time within 2
years was observed in the DTA in 21 patients and in
the AA in 21 patients; a majority of these patients had
acute dissection (17/21 for DTA, 20/21 for AA).
Mortality, rupture, conversion, and secondary interven-
tion were not signiﬁcantly different between patients
with and without transaortic growth. A generalized linear
model indicates that a shorter time from symptom onset
to treatment predicts transaortic growth in both the
DTA (P ¼ .03) and AA (P < .001), and a higher SVS
risk score for hypertension predicts growth in the AA
(P ¼ .04).
Conclusions: Endovascular repair of cTBAD using
a composite construct demonstrates favorable aortic
remodeling. However, patients treated in the acute setting
may be prone to aortic growth and require close observa-
tion. Follow-up through 5 years is ongoing.Fig. Maximum diameters of the true lumen, false lumen, and total
lumen in the descending thoracic aorta (DTA) and abdominal aorta
(AA) (least square means estimated from a general linear model).
The increase in true lumen size and decrease in false lumen size
were statistically signiﬁcant in both aortic segments from pre-
procedure to 2 years (P < 0.001). Number of patients with avail-
able total lumen measurements is indicated for each time point.
Fig. The yellow (celiac axis), green (right renal), and blue (lef
a ﬁxed point (red dot) based on the superior mesenteric arter
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Anatomical Feasibility of Off-the-Shelf Fenestrated
Stent Grafts to Treat Juxtarenal and Pararenal
Abdominal Aortic Aneurysms
Bernardo Mendes, Gustavo S. Oderich, Stephen Cha,
Audra A. Duncan, Manju Kalra, Mark Fleming, Peter
Gloviczki, Thanila Macedo, Thomas C. Bower. Division
of Vascular and Endovascular Surgery, Mayo Clinic,
Rochester, Minn
Objectives: To evaluate the anatomical feasibility of
two off-the-shelf fenestrated stent-grafts to treat juxtarenal
(JRA) and pararenal (PRA) abdominal aortic aneurysms
(AAAs).
Methods: Digital computed tomography angiography
was analyzed in 520 consecutive patients treated with open
or fenestrated endovascular repair for complex AAAs
between 2000-2012. The anatomical feasibility of two
off-the-shelf fenestrated designs - Endologix Ventana
(Irvine, California) and Cook p-Branch (Brisbane,
Australia) - was analyzed using Instructions for Use
(IFU) proposed by investigational protocols.t renal) dots indicate location of each artery in relation to
y. The blue-shaded area indicates range of visceral artery
